vs
Side-by-side financial comparison of FLOWERS FOODS INC (FLO) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
FLOWERS FOODS INC is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 2.0× Royalty Pharma plc). On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -75.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -11.6%).
Flowers Foods, headquartered in Thomasville, Georgia, is a producer and marketer of packaged bakery foods in the United States. The company operates 44 bakeries across 19 states that produce a variety of products, including bread, buns, rolls, snack cakes, pastries, and tortillas. As of February 2013, Flowers Foods had grown to be the "second-largest baking company in the United States."
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
FLO vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $622.0M |
| Net Profit | — | $214.2M |
| Gross Margin | — | — |
| Operating Margin | — | 62.4% |
| Net Margin | — | 34.4% |
| Revenue YoY | -75.8% | 4.8% |
| Net Profit YoY | — | 2.9% |
| EPS (diluted) | — | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $622.0M | ||
| Q3 25 | $1.2B | $609.3M | ||
| Q2 25 | $1.6B | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $1.2B | $593.6M | ||
| Q3 24 | $1.2B | $564.7M | ||
| Q2 24 | $1.6B | $537.3M | ||
| Q1 24 | — | $568.0M |
| Q4 25 | $39.5M | $214.2M | ||
| Q3 25 | $58.4M | $288.2M | ||
| Q2 25 | $53.0M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $65.0M | $208.2M | ||
| Q3 24 | $67.0M | $544.0M | ||
| Q2 24 | $73.0M | $102.0M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | 5.4% | 62.4% | ||
| Q3 25 | 7.5% | 70.1% | ||
| Q2 25 | 5.5% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | 7.6% | 60.9% | ||
| Q3 24 | 7.8% | — | ||
| Q2 24 | 6.4% | 50.2% | ||
| Q1 24 | — | -13.0% |
| Q4 25 | 3.2% | 34.4% | ||
| Q3 25 | 4.7% | 47.3% | ||
| Q2 25 | 3.4% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | 5.5% | 35.1% | ||
| Q3 24 | 5.5% | 96.3% | ||
| Q2 24 | 4.6% | 19.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | $0.19 | $0.49 | ||
| Q3 25 | $0.28 | $0.67 | ||
| Q2 25 | $0.25 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $0.31 | $0.46 | ||
| Q3 24 | $0.32 | $1.21 | ||
| Q2 24 | $0.34 | $0.23 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.1M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | — | $9.7B |
| Total Assets | $4.2B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.7M | $618.7M | ||
| Q3 25 | $11.0M | $938.9M | ||
| Q2 25 | $7.3M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $15.0M | $929.0M | ||
| Q3 24 | $6.9M | $950.1M | ||
| Q2 24 | $15.8M | $1.8B | ||
| Q1 24 | — | $843.0M |
| Q4 25 | $1.8B | $9.0B | ||
| Q3 25 | $1.7B | $8.9B | ||
| Q2 25 | $1.8B | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | $1.1B | $7.6B | ||
| Q2 24 | $1.0B | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.4B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | $1.4B | $10.3B | ||
| Q2 24 | $1.4B | $9.8B | ||
| Q1 24 | — | $9.9B |
| Q4 25 | $4.3B | $19.6B | ||
| Q3 25 | $4.3B | $19.3B | ||
| Q2 25 | $4.3B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $3.4B | $18.2B | ||
| Q3 24 | $3.4B | $18.0B | ||
| Q2 24 | $3.4B | $17.7B | ||
| Q1 24 | — | $16.1B |
| Q4 25 | 1.25× | 0.92× | ||
| Q3 25 | 1.23× | 0.93× | ||
| Q2 25 | 1.26× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.75× | 0.74× | ||
| Q3 24 | 0.77× | 0.74× | ||
| Q2 24 | 0.76× | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $125.4M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.4M | $827.1M | ||
| Q3 25 | $130.8M | $702.6M | ||
| Q2 25 | $135.6M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $113.9M | $742.5M | ||
| Q3 24 | $63.3M | $703.6M | ||
| Q2 24 | $105.1M | $658.2M | ||
| Q1 24 | — | $664.6M |
| Q4 25 | $30.4M | — | ||
| Q3 25 | $100.0M | — | ||
| Q2 25 | $110.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $88.6M | — | ||
| Q3 24 | $35.4M | — | ||
| Q2 24 | $71.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.5% | — | ||
| Q3 25 | 8.0% | — | ||
| Q2 25 | 7.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 4.6% | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.38× | 3.86× | ||
| Q3 25 | 2.24× | 2.44× | ||
| Q2 25 | 2.56× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 1.75× | 3.57× | ||
| Q3 24 | 0.94× | 1.29× | ||
| Q2 24 | 1.44× | 6.45× | ||
| Q1 24 | — | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLO
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
